← Back to Search

RGN-137 for Epidermolysis Bullosa (CELEB Trial)

Phase 2
Waitlist Available
Research Sponsored by Lenus Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 84
Awards & highlights

CELEB Trial Summary

This study is evaluating whether a gel may help treat a rare skin condition.

Eligible Conditions
  • Epidermolysis Bullosa

CELEB Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to achieving 50% reduction in area of each index wound from Day 1 up to Day 84.
Secondary outcome measures
Change from Baseline and percent change from Baseline in surface area of each index wound at the scheduled visits.
Incidence of 50%, 75%, and 100% reduction and complete re-epithelialization without drainage in area of each index wound at the scheduled visits.
Time to achieving 50%, 75%, and 100% (with drainage or without drainage) reduction in area of each index wound from Day 1 up to Day 84.
Other outcome measures
Index wound characteristics at the scheduled visits.

CELEB Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RGN-137Experimental Treatment1 Intervention
It is formulated as a gel for topical administration.
Group II: PlaceboPlacebo Group1 Intervention
It is composed of the same excipients as RGN-137 formulation without the active ingredient.

Find a Location

Who is running the clinical trial?

Lenus Therapeutics, LLCLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
2019. "Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03578029.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top